Nov. 8, 2013
/PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax
personalized immune therapies for solid tumor cancers, announced today that their vaccine was featured yesterday in news coverage on both Fox News and Fox Business News.
The segment was hosted for Fox by Dr.
, a Clinical Associate Professor at
Langone Medical Center, who describes Northwest Biotherapeutics's DCVax as a potential life-extending treatment for all solid tumor cancers by using biomarkers from the patient's own tumor cells to activate the patient's immune system to fight the cancer in the patient's body.
, participating in a current late stage Phase III trial of the DCVax immune therapy for brain cancer at the Long Island Brain Tumor Center, describes the process that begins with surgical removal of the patient's tumor. The patient's immune cells are then harvested and exposed in the laboratory to the biomarkers taken from the patient's tumor. These conditioned immune cells are then injected back into the patient through a simple injection under the skin in the upper arm, similar to a flu shot. The conditioned ("educated") immune cells then mobilize the patient's immune system to now fight any tumor cells bearing the same biomarkers wherever such tumor cells are found in the body.
According to Dr. Siegel, some patients with Glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, in preliminary trials have seen their survival times more than double from what would be expected under the current standard of care (which consists of surgical removal of the tumor, radiation and chemotherapy). The final (Phase III) stage of DCVax clinical trials for GBM is being conducted at more than 50 sites across the US, as well as in
"Each cancer vaccine is personalized, and it takes just eight days to produce enough for three-to-five years' worth of treatment," remarks Dr. Siegel. "It's more cost-effective than older cancer vaccines, and the side effects are minimal versus standard treatments."